further underlined by studies in mice deficient in Nrf1 (17) , Nrf2 (18) , SOD2 (70) , GSH peroxidase 4 (102), or FoxO3 (75) , which suffer from either prenatal lethality associated with impaired erythropoiesis or severe postnatal anemia. Moreover, oxidative stress is a well-known inducer of suicidal death of mature erythrocytes, the so-called eryptosis (59) , which may be triggered by opening of Ca 2ϩ -permeable cation channels in the cell membrane (29, 60) . The following Ca 2ϩ entry induces cell membrane scrambling with phosphatidylserine (PS) exposure at the erythrocyte surface (7, 15, 62) . PS-exposing cells in turn bind to macrophages (26, 41) with subsequent phagocytosis and thus clearance from circulating blood (50) . The increase of cytosolic Ca 2ϩ concentration further stimulates Ca 2ϩ -sensitive K ϩ channels (16) leading to cellular loss of KCl and osmotically obliged water (45, 66) . The resulting cell shrinkage contributes to the triggering of suicidal erythrocyte death (89) . The ability of oxidative stress to trigger death of erythrocytes has been disclosed more than three decades ago (86) .
Cell membrane scrambling is likewise triggered by infection with the intraerythrocyte parasite Plasmodium (19, 33, 43, 53, 54, 78, 90) , which imposes oxidative stress on the host cell (6, 43) . Accelerated eryptosis and clearance of parasitized erythrocytes is expected to counteract the development of parasitemia and is thus considered a protective mechanism against malaria (28, 91) . Accordingly, enhanced susceptibility to eryptosis and the ensuing clearance of Plasmodium-infected erythrocytes may contribute to the relative resistance against a severe course of malaria in carriers of several genetic erythrocyte disorders, such as sickle-cell trait, ␤-thalassemia trait, and glucose-6-phosphate dehydrogenase (G6PD) deficiency (4, 64) . Moreover, stress-or drug-induced erythrocyte clearance may also protect infected hosts against malaria, as has been demonstrated in iron deficiency (53) as well as following treatment of mice with eryptosis-inducing agents, such as lead (54) , chlorpromazine (55) , Paclitaxel (52) , or cyclosporine (13, 57) .
Presumably, GSH presents an ideal target to limit the survival of Plasmodium-infected erythrocytes that are oxidatively stressed and already show a disbalanced level of oxidized and reduced GSH. One small molecule that is known to affect intracellular GSH is the bioactive fumaric acid ester (FAE) dimethylfumarate (DMF), which is in clinical use for immune disorders (31, 80) . Safety and efficacy of DMF and related FAE have been shown for the therapy of psoriasis and for the therapy of multiple sclerosis (1, 47 ). Yet, the exact underlying mechanisms mediating the effect of DMF on the immune system are not fully understood. DMF is highly lipophilic and thus easily enters cells. The cytosolic concentration, however, cannot be predicted. When added to the extracellular fluid, DMF triggers apoptosis in lymphocytes (97) and provides immune-modulating effects (32, 69) . These effects seem to be partly mediated by cellular glutathione depletion and oxidative stress (69, 88) . DMF does not influence the equilibrium of reduced GSH and oxidized glutathione (GSSG) by inhibiting GSH reductase and/or modulating GSH peroxidase activity. Instead, DMF depletes GSH by formation of covalently linked conjugates with GSH (88) . In the following, GSSG is converted to GSH and will also be depleted by DMF. Thus DMF treatment results eventually in a significant decrease of the cellular content of both GSH and GSSG content. The present study explored whether DMF may also affect the life span of erythrocytes due to GSH depletion and induction of oxidative stress. In a first step, the proeryptotic effects of DMF on erythrocytes were tested in vitro. DMF-induced impairment of antioxidative defense was disclosed by measuring GSH and GSSG levels after DMF treatment. The functional significance of GSH depletion in the triggering of cell membrane scrambling was tested by the use of the reducing agent N-acetyl-Lcysteine (NAC). To verify the hypotheses that stressed erythrocytes may be more susceptible to DMF and that DMF may thus be effective against intracellular parasites, we measured the influence of DMF on the GSH levels of Plasmodium falciparum-infected human erythrocytes and determined intraerythrocyte DNA amplification and parasite growth after challenge with DMF. In a proof of principle experiment, we further demonstrated that a therapeutically established dose of DMF inhibits parasitemia and increases host survival during Plasmodium berghei-induced malaria in vivo.
MATERIALS AND METHODS
Erythrocytes and solutions. Erythrocyte concentrates, which have been purified from whole blood by using the OptiPure RC quadruple blood pack set equipped with a soft housing red cell filter from Baxter (Unterschleissheim, Germany) (51), were obtained from the blood bank in Tübingen (Ottfried-Müller Str. 4/1, 72076 Tübingen, Germany). Aliquots of the individual erythrocyte concentrates were either used directly at 0.4% hematocrit (unless noted differently) or stored at 4°C until usage. Experiments were performed at 37°C in Ringer solution containing (in mM) 125 NaCl, 5 KCl, 1 MgSO4, 32 N-2-hydroxyethylpiperazine-N=-2-ethanesulfonic acid (HEPES)/NaOH (pH 7.4) 5 glucose, and 1 CaCl2. For energy depletion, glucose (5 mM) was omitted from the NaCl Ringer solution. Where indicated, the Ca 2ϩ ionophore ionomycin (0.1 M), NAC (1 mM), and DMF (7-140 M) were added. The substances were dissolved in final concentrations of 0.2% dimethyl sulfoxide (DMSO) (ionomycin, DMF). Ionomycin, NAC, and DMF were purchased from Sigma (Taufkirchen, Germany). The study on human erythrocytes was approved by the Ethical Commission of the University of Tübingen.
Hemolysis. Erythrocyte concentrates (0.4% hematocrit) were treated with varying concentrations of DMF, and hemolysis was determined as described previously (65) . After incubation, the samples were centrifuged (4 min at 400 g) at 4°C and the supernatants were harvested. As a measure of hemolysis, the Hb concentration of the supernatant was determined photometrically at 405 nm. The absorption of the supernatant of erythrocytes lysed in distilled water was defined as 100% hemolysis.
FACS analysis. To evaluate PS exposure in red blood cells (RBC), flow cytometric analysis was performed as described previously (60) . Erythrocyte concentrates (0.4% hematocrit) were treated with varying concentrations of DMF. After incubation, 100 l of the cells were washed in annexin-binding buffer containing (in mM) 125 NaCl, 10 HEPES (pH 7.4), and 5 CaCl 2. Erythrocytes were then stained with Annexin-Fluos (Roche Diagnostics, Mannheim, Germany) at a 1:35 dilution and mixed gently on a vortex mixer. FITC-labeled annexin V binds to phosphatidylserine being exposed on the outer leaflet of the plasma membrane. After 20 min of incubation in the dark at room temperature, samples were diluted 1:5, thoroughly mixed to obtain suspensions of dissociated cells, and measured by flow cytometric analysis (FACS-Calibur from Becton Dickinson, Heidelberg, Germany). Cells were analyzed by forward scatter, and annexin-fluorescence intensity was measured in FL-1 with an excitation wavelength of 488 nm and an emission wavelength of 530 nm.
For determination of PS exposure ex vivo in the presence or absence of DMF, suspensions of P. berghei-infected erythrocytes were stained with annexin V-APC (BD Biosciences Pharmingen, Heidelberg, Germany) and/or with the DNA/RNA-specific dye Syto16 (Molecular Probes, Göttingen, Germany) to identify PSexposing and infected erythrocytes, respectively. For annexin V binding, erythrocytes from mice at day 14 after infection were washed, resuspended in annexin V-binding buffer (Ringer solution containing 5 mM CaCl 2, pH 7.4), stained with annexin V-APC (dilution 1:20), incubated for 20 min at room temperature, and diluted 1:5 with annexin V-binding buffer. Syto16 (final concentration of 20 nM) was added directly to the diluted erythrocyte suspension or coincubated in the annexin V-binding buffer. Cells were analyzed by flow cytometry in FL-1 for Syto16 (detected at 530 nm) and in FL-4 for annexin V-APC fluorescence intensity (detected at 660 nm).
Fluorescence microscopy. Fluorescence microscopy was performed essentially as described previously (61) . After incubation with DMF, erythrocytes were stained with Annexin-Fluos as described above. After cells were washed with annexin buffer, 10 l of the suspension were applied to a slide and covered with a coverglass. concentration of erythrocytes treated with DMF were observed for up to 6 h (data not shown), the cells were first pretreated with DMF for 48 h, centrifuged, and then resuspended in Fluo3/AM-containing buffer as described above. To determine the Fluo3/AM-loading capacity of DMF-and vehicle-pretreated erythrocytes, ionomycin was added to some cell suspensions, and ionomycin-treated erythrocytes were used as an internal control.
Determination of intracellular ATP concentration. The firefly luciferase assay (ATP Bioluminescence Assay Kit HS II, Roche Diagnostics) was used for determination of ATP concentrations as described earlier (51) . Erythrocyte concentrates (5% hematocrit) were incubated for 24 and 48 h at 37°C with standard Ringer solution with or without 140 M DMF. For ATP depletion (as positive control), glucose (5 mM) was omitted from standard Ringer solution. After incubation, cells were washed three times in PBS at 3,600 rpm for 5 min at 4°C, and then lysed (50 l) in 700 l distilled water. Proteins were precipitated by 500 l chaotropic reagent perchloric acid (6%).
After incubation (10 min on ice) and centrifugation (10 min at 14,000 rpm at 4°C), an aliquot of the supernatant (400 l) was neutralized by addition of 45 l saturated KHCO 3 solution. The precipitate was then removed by centrifugation at 10,000 rpm at 4°C for 8 min. The aliquot from the supernatant was diluted 20-fold with Ringer solution (pH 7.8), and 100 l of this extract was used for ATP measurements. For the analysis of ATP, 100 l of Ringer solution (pH 7.8), sample extract, or ATP standard solution were placed in polystyrene test tubes followed by the addition of 40 l luciferase solution. The luminescence signal was measured in a luminometer (Berthold Biolumat LB9500; Bad Wildbad, Germany) according to the manufacturer's protocol. ATP concentrations are expressed as percentage of Ringertreated controls.
Glutathione measurement. GSH refers to the reduced form of glutathione and GSSG to the oxidized disulfide dimer. GSx refers to the tripeptide unit of unspecified oxidation state (GSH equivalents) and was quantified in a microtiter plate according to the technique of Dringen and Hamprecht (21) using the method originally described by Tietze (96) . The samples (cell extracts) and standards were processed through exactly the same procedure. The samples and standards were kept on ice until being loaded into the microtiter plate. Ten microliters of the cell lysates or standards containing from 0 -600 pmol of GSx/10 l were transferred into wells of microtiter plates and diluted with 90 l of water, yielding final concentrations of 0.1% sulfosalicylic acid. After addition of 100 l of reaction mixture [0.1 M sodium phosphate buffer (pH 7.5) containing 1 mM EDTA, 0.3 mM 5,5=-dithiobis(2-nitrobenzoic acid) (DTNB), 0.4 mM NADPH, and 1 U/ml glutathione reductase], the increase in extinction at 405 nm was detected in 30-s intervals over a range of 5 min using a microtiter plate reader (Multiskan EX; Thermo Electron, Erlangen, Germany). Gluta- thione contents were evaluated by using a calibration curve established with standard samples. Glutathione disulfide was quantified after derivatization of reduced glutathione with 2-vinylpyridine (2VP) to conjugate GSH before assaying of residual GSSG. In brief, 130 l of the protein-free supernatant was mixed with 5 l of undiluted 97% 2VP and adjusted with 0.2 M Tris-Base (Sigma-Ultra) to pH 5. Standard samples with defined GSSG concentrations were treated the same way. After a 1-h incubation at room temperature, 10 l of the 2VP-treated samples or standards were assayed as described above using a calibration curve established between 0 and 600 pmol of GSSG per well. The extinction at 405 nm was followed over a 5-min period in 30-s intervals. Erythrocytes concentrates (0.4% or 5% hematocrit as indicated) were treated with varying concentrations of DMF. After 24-h incubation, 1 ml of the cells was washed two times with PBS and assayed as described above.
In vitro measurement of parasite growth inhibition and DNA amplification. For infection of human erythrocytes, the human pathogen P. falciparum strain BinH (11) was grown in vitro (43) and synchronized to the ring stage by sorbitol treatment as described previously (22) . Parasites were cultured as described earlier (44) at a hematocrit of 2% and a parasitemia of 2-10% in RPMI 1640 medium complemented with 5 mM HEPES/NaOH (pH 7.4), 2 mM glutamine, and 20 g/ml gentamycin supplemented with Albumax II (0.5%; GIBCO, Karlsruhe, Germany) in an atmosphere of 90% N2, 5% CO2, 5% O 2 (14, 56) . The parasites were cultured in a candle jar (with gas environment of about 3% O 2, 6% CO2, and 91% N2) at 37°C. Stock solutions of DMF were prepared in DMSO (Applichem, Darmstadt, Germany) and diluted in complete culture medium to a final concentration of 1 to 140 M. The drug was then added to sorbitolsynchronized parasite cultures (containing only ring stage) in 96-well plates (200-l aliquots, 0.5-1% parasitemia and 1% final hematocrit). The growth inhibition for various DMF concentrations was determined by comparison of the parasitemia in the treated culture with that in the control culture (without DMF) maintained on the same plate at time 0 and after 48 h by flow cytometry. To estimate the DNA/RNA amplification, the parasite cultures were ring stage-synchronized, and resynchronized after 6 h of culture (to narrow the developmental parasite stage), aliquoted (200 l aliquots, 10% parasitemia and 2% hematocrit), and incubated for further 16 h in the presence or absence of DMF (1 to 140 M). Parasitemia was defined by the percentage of RBC stained with the DNA/RNA-specific fluorescence dye Syto16 (30 nM final concentration). The DMF concentration causing 50% inhibition (IC50) was obtained from the concentration-response curve. DMSO concentration in the cultures never exceeded 0.2% and did not affect parasite growth.
In vivo measurement of parasite growth and antimalarial efficacy of DMF. The animal experiments were performed according to German animal protection law and were approved by local authorities (registration no. PY 2/06). Animal experiments were performed in healthy SV129/J wild-type mice (aged 4 mo, both male and female, body weight 20 Ϯ 2 g). Blood was drawn by incision of the tail vein. For infection of mice, an aliquot (0.2 ml) of P. berghei ANKAparasitized murine erythrocytes (1 ϫ 10 6 ) were injected intraperitoneally (42, 58) at day 0 into experimental and control groups of mice (n ϭ 10 -12/group). Experimental mice were maintained on DMFcontaining water at doses of 50 mg/kg body wt 10 days before infection for a total of 6 wk. Cure was defined as survival until day 41 posttreatment (oral dosing). Blood smears were taken 8 days after parasite inoculation daily, and mortality was monitored for further 4 wk. Throughout the experiments, animals received autoclaved tap water and food ad libitum and were kept in an air-conditioned animal room at 22-23°C.
Statistical analysis. Data are expressed as arithmetic means Ϯ SE, and statistical analysis was made by t-test or ANOVA using Tukey's test as post hoc test, as appropriate. P Ͻ 0.05 was considered as statistically significant.
RESULTS

Induction of PS exposure by DMF in vitro.
Cell membrane scrambling, a hallmark of eryptotic cells, was identified by determination of annexin V-binding at the cell surface in FACS analysis. As shown in Fig. 1, A and B, exposure of human erythrocytes for 24 h to 7-140 M DMF led to a concentration-dependent increase of the percentage of annexin V-binding erythrocytes. Phosphatidylserine-exposing erythrocytes further accumulated after 48 h, when a maximum of 37.8 Ϯ 2.1% annexin V-positive cells was observed in the presence of 140 M DMF. After 24 and 48 h, the effect reached statistical significance at DMF concentrations of Ն35 M. DMF-induced annexin V binding was apparently independent of the blood group of the erythrocyte donors (e.g., A ϩ erythrocytes from one volunteer showed a 23-fold and O ϩ erythrocytes from another volunteer a 25-fold induction of annexin V-positive cells after 48 h DMF treatment).
Exposure of human erythrocytes to DMF was further followed by cell shrinkage, which constitutes a second hallmark of eryptosis. Cell shrinkage was determined from erythrocyte forward scatter in FACS analysis. As illustrated in Fig. 1C , DMF concentration dependently decreased the erythrocyte forward scatter after 24 and 48 h of incubation. This effect reached statistical significance at DMF concentrations of Ն70 M.
To possibly disclose DMF-induced hemolysis, DMF-and vehicle-treated cells were stained with FITC-labeled annexin V and then analyzed by fluorescence microscopy. In these experiments, control erythrocytes showed a normal disc-like shape (Fig. 1D, inset top left) , and only low amounts of the cells were annexin V-positive (Fig. 1D, bottom left) . In contrast, a significant quantity of DMF-treated erythrocytes was annexin Vpositive (Fig. 1D, bottom right) . Interestingly, some DMFtreated erythrocytes were annexin V positive (Fig. 1D , inset bottom right) and simultaneously showed a shrunken phenotype, resembling echinocytes (Fig. 1D, inset top right) . To additionally quantify hemolysis, the hemoglobin concentration was determined in the supernatant of erythrocytes following 48 h of exposure to Ringer solution in the presence of different concentrations of DMF. As shown in Fig. 1E , DMF did not appreciably induce hemolysis up to a concentration of 140 M. Thus, DMF stimulated cell membrane scrambling and decreased cell volume without disrupting the integrity of the cell membrane.
Increased Ca 2ϩ influx following DMF-induced GSH depletion. Additional experimental efforts addressed the mechanisms underlying DMF-induced eryptosis. Because increase of cytosolic Ca 2ϩ activity triggers both cell membrane scrambling and cell shrinkage, Fluo3 fluorescence has been utilized to elucidate whether DMF influences the erythrocyte Ca 2ϩ concentration. However, initial experiments revealed that DMF did not have any significant direct effect on intracellular erythrocyte Ca 2ϩ activity during the first 6 h of incubation (data not shown). We therefore preincubated the cells for 48 h and then measured Fluo3-dependent fluorescence as an indicator of intracellular Ca 2ϩ concentration. As shown in Fig. 2, A and B, the exposure of human erythrocytes to DMF for 48 h led to a significant increase of the percentage of Fluo3-positive cells, pointing to the induction of erythrocyte populations with higher cytosolic Ca 2ϩ activities. The percentage of DMFtreated cells with high Ca 2ϩ activities strongly increased over time, whereas control cells showed only marginal differences after 3 h of Fluo3 labeling (Fig. 2B) . To rule out the possibility of differences in dye loading, the erythrocytes were treated with the Ca 2ϩ ionophore ionomycin, which should load the cells with dye-saturating concentrations of Ca 2ϩ . As a result, following ionomycin treatment, all cells were Fluo3 positive and the fluorescence was similar in DMF-treated and vehicletreated erythrocytes, pointing to equal dye loading (Fig. 2C) . The results demonstrate that prolonged DMF treatment of erythrocytes does lead to increase of intracellular Ca 2ϩ . Ca 2ϩ entry could be triggered by energy depletion. Accordingly, erythrocyte ATP concentration was determined in erythrocytes with or without prior exposure to DMF. As shown in Fig. 3A , 140 M DMF did not significantly decrease the erythrocyte ATP content after 48 h, indicating that energy depletion is not involved in DMF-induced erythrocyte death. For comparison and as a positive control, exposure of erythrocytes to glucose-depleted media was followed by the expected marked and statistically significant decrease of the erythrocyte ATP content (Fig. 3A, right column) .
The Ca 2ϩ -permeable erythrocyte cation channel is also activated by oxidative stress, which may result from impaired antioxidative defense during GSH depletion. Thus, additional experiments were performed to disclose an effect of DMF on erythrocyte GSH content. As a matter of fact, exposure of erythrocytes to 70 and 140 M DMF for 48 h under the same experimental conditions as described for the ATP measurements (5% hematocrit) was followed by significant reduction of intracellular GSH (Fig. 3B) . To investigate this effect in more detail, we used the same conditions as described in Figs. 1 and 2 (0.4% hematocrit) and treated erythrocytes with different concentrations of DMF and measured GSH and GSSG content of the cells. Interestingly, DMF did not only concentration dependently deplete GSH levels (Fig. 3C) but also decreased the levels of the oxidized form of glutathione, i.e., GSSG, with an IC 50 of ϳ20 M (Fig. 3D) .
Prevention of DMF-induced eryptosis by antioxidants. If DMF would be effective mainly by inducing oxidative stress, the application of a reducing substance should blunt DMFinduced eryptosis. Thus, experiments were performed in the absence and presence of the reducing substance NAC. As illustrated in Fig. 4 , A and B, the addition of 1 mM NAC virtually abolished the effect of 70 and 140 M DMF on annexin V binding. Similarly, NAC pretreatment prevented DMF-induced cell shrinkage as evidenced by normalization of the forward scatter (Fig. 4C) . In an additional experimental setup, we treated human erythrocytes with DMF in the presence or absence of NAC and then measured annexin V binding and erythrocyte GSH content in parallel. In those experiments, there was an inverse correlation between annexin V binding and the reducing capacity of the cells, i.e., in the presence of DMF alone, annexin V binding was high and GSH levels were low (Fig. 4D, top 3rd column and bottom 3rd column,  respectively) . In contrast, addition of NAC to DMF-treated cells blunted annexin V binding and restored the GSH levels to normal values (Fig. 4D, top 4th column and bottom 4th  column, respectively) .
To further exclude that DMF was effective through interference with energy generation from glucose, we added DMF in the presence and absence of glucose. Glucose withdrawal from the Ringer solution was followed by the expected increase of annexin V binding (Fig. 5, A and B) and decrease of forward scatter (Fig. 5C) , effects, augmented in the presence of DMF (Fig. 5, A-C) . The additive effect of DMF on annexin V binding, but not that on forward scatter, was statistically significant. These data also argue against a main role of energy depletion in the DMF-mediated effect on erythrocyte cell membrane scrambling. They clearly demonstrate, however, that stressed human erythrocytes are more susceptible to a challenge with DMF.
Prevention of plasmodium proliferation by DMF-induced GSH depletion. Infection of human erythrocytes with parasites such as P. falciparum can likewise be considered as a special kind of cellular stress leading to slow-paced erythrocyte death. Since accelerated eryptosis has previously been shown to modify the development of parasitemia and affects the clinical course of malaria, additional experiments were performed elucidating the effect of DMF on the in vitro growth of P. falciparum in human erythrocytes as well as the in vivo parasitemia and survival of P. berghei-infected mice. For this, the P. falciparum-infected human erythrocytes were synchronized to ring stage by sorbitol treatment. As shown in Fig. 6A , the intraerythrocyte DNA amplification of P. falciparum-infected human erythrocytes was concentration dependently inhibited by DMF treatment with an IC 50 of 40 M. The treatment with DMF further decreased the percentage of infected erythrocytes after 48 h (Fig. 6B) . The effect on parasitemia reached statistical significance at DMF concentrations Ն10 M and displayed an IC 50 of ϳ30 M (Fig. 6B) .
Additional experiments were performed to determine the effect of infection and DMF on human erythrocyte GSH content. While infection in the absence of DMF was followed by a small but significant decrease of erythrocyte GSH content (Fig. 6C) , the presence of DMF resulted in a marked concentration-dependent decrease of the erythrocyte content of both, GSH (Fig. 6D, left) and GSSG (Fig. 6D, right) . Thus, DMF treatment accelerates depletion of GSH stores from infected compared with noninfected erythrocytes (see also Fig. 3, C  and D) .
Further experiments again aimed to elucidate the role of oxidative stress. First, we showed that the reducing agent NAC completely reversed the DMF-induced inhibition of parasitemia (Fig. 6E) . In another experimental setup, DNA ampli- fication and GSH content of infected human erythrocytes were measured in parallel after treatment with DMF in the presence or absence of NAC. As expected, DMF markedly decreased the DNA amplification (Fig. 6F ) and GSH level (Fig. 6G) of infected human erythrocytes. Most importantly, both effects were virtually abolished in the presence of the reducing agent NAC (Fig. 6, F and G) , thereby directly linking intraerythrocyte parasite growth and antioxidative defense.
Protection against parasitemia and P. berghei-induced death by DMF-induced GSH depletion in vivo.
The in vitro observations on DNA content and parasitemia of P. falciparum-infected human erythrocytes suggested a favorable effect of DMF treatment in vivo. Before treatment of infected mice, DMF was administered to noninfected 129-SVJ mice to explore whether DMF treatment (2.08 mM in drinking water) is followed by clinically relevant anemia. As illustrated in Fig. 7 , DMF treatment of healthy mice for up to 16 wk did not result in statistically significant alterations of packed cell volume (left), RBC count (middle), and GSH content (right) of circulating erythrocytes. Thus, DMF treatment of mice did not exert any appreciable effects on unstressed erythrocytes at therapeutically established concentrations.
To determine the in vivo effect of DMF on the course of malaria, 129-SVJ mice were treated with DMF (2.08 mM in drinking water). At the 8th day of infection, parasitemia of control and DMF-treated mice was still low (Fig. 8A) . The percentage of infected erythrocytes steadily increased in both experimental groups until day 11. However, at day 12, parasitemia of DMF-treated mice was already lower than without DMF treatment, and parasitemia of these mice returned to baseline on day 14, while it continued to increase in the sham-treated group. The difference between both groups reached statistical significance at day 13 (Fig. 8A) .
Importantly, DMF treatment conferred survival of the majority of mice infected with an otherwise lethal dose of P. berghei. As shown in Fig. 8B , all untreated animals died within 14 days after the infection, whereas 60% of the DMF-treated animals survived the same infection for Ͼ30 days. DMFtreated uninfected mice remained clinically healthy. These data demonstrate that DMF protected infected mice against a deadly course of malaria.
In a further series of experiments, we used a protocol to measure ex vivo PS exposure of erythrocytes drawn from infected mice in the presence or absence of DMF (2.08 mM in drinking water). As shown in Fig. 8 , C and D, DMF increased the percentage of PS exposure in infected erythrocytes from mice at day 14 of infection ( Fig. 8D) , whereas noninfected erythrocytes (Fig. 8C) remained unaffected.
DISCUSSION
The present study reveals that depletion of intracellular GSH in erythrocytes by DMF treatment is followed by cell shrinkage and stimulation of cell membrane scrambling, both typical features of suicidal cells. Importantly, sublethal GSH depletion by therapeutically established dosage of DMF sensitized erythrocytes to the triggering of PS exposure by infection with Plasmodium. It thus blunted the development of parasitemia and counteracted a deadly course of malaria in P. bergheiinfected mice. DMF dose dependently stimulated PS exposure, the programmed death of erythrocytes (7, 15, 59, 62) . GSH depletion in erythrocytes is accompanied by oxidative stress. The critical role of oxidative stress in the triggering of suicidal erythrocyte death was documented by the reversal of the eryptotic effect of DMF following addition of the antioxidant NAC, which provides cysteine to accelerate GSH synthesis in erythrocytes (85) .
Erythrocytes are known to be sensitive to oxidative stress (10, 20) , which may open Ca 2ϩ -permeable cation channels (23) . DMF indeed increased cytosolic Ca 2ϩ activity. It is not clear, however, whether the DMF-induced cell membrane scrambling was indeed due to activation of Ca 2ϩ channels, because the DMF-induced effect was only observed after long-term preincubation (48 h) with DMF. Nevertheless, Ca 2ϩ at least contributes to the stimulation of DMF-induced PS exposure. The same is true for the morphological changes of DMF-treated erythrocytes which occasionally resemble echinocytes. The DMF-induced increase of the cytosolic Ca 2ϩ concentration and the subsequent stimulation of Ca 2ϩ -sensitive K ϩ channels leads to cellular loss of KCl and osmotically obliged water, i.e., erythrocyte dehydration, which is among others a well-known trigger of echinocytosis. In addition, oxidative stress activates erythrocyte Cl Ϫ channels (24, 43, 95) , which are required for Cl Ϫ exit, erythrocyte shrinkage, and thus also participate in the triggering of eryptosis (81) . Oxidative stress has further been shown to activate aspartyl-and cysteinyl-proteases (76) . Moreover, erythrocytes express oxidant-sensitive caspases (15, 74) . Thus, oxidative stress may be effective by triggering several distinct mechanisms eventually leading to suicidal erythrocyte death.
PS-exposing erythrocytes are rapidly phagocytosed (12, 101) and disappear from circulating blood (50) . Thus, even in conditions with substantially accelerated PS exposure as in the case of DMF treatment, only a few annexin V-binding cells are expected in freshly drawn blood. However, in P. berghei-infected mouse erythrocytes, we could demonstrate a significantly enhanced PS exposure in DMF-treated mice compared with control mice.
The accelerated clearance of PS-exposing erythrocytes may be partially or fully compensated by enhanced formation of new erythrocytes, which may prevent the development of clinically relevant anemia (59) . Thus, it is not astonishing that despite the established clinical use of DMF, clinical significant anemia (87, 99) has not been reported in the literature as side effects of the drug (1, 47) . Our experimental data using healthy wild-type mice confirm the clinical observations that orally applied DMF does not induce clinical relevant anemia or clinical relevant changes in blood parameters. Thus, in our in vivo setting with no infections or cellular stress, the GSH metabolism of intact erythrocytes is not profoundly altered by DMF, at least not to an extent that would result in significant PS exposure. This may be due to transport of amino acids across the erythrocyte membrane contributing to cell viability by providing precursors for intracellular GSH biosynthesis (25) . Furthermore, it is known that the efflux of GSH from liver provides over 90% of total GSH inflow in the circulation (for review see Ref. 5) , resulting in an additional extracellular source for GSH.
Nevertheless, accelerated eryptosis contributes to anemia in a variety of clinical conditions, such as iron deficiency (50), sickle-cell anemia (38, 100), ␤-thalassemia (62), G6PD deficiency (62), "hemolytic uremic syndrome" (63) , sepsis (49) , malaria (28) , and Wilson disease (68) . Moreover, eryptosis is triggered by a wide variety of substances (for review see Ref. 59 ). Some of these conditions causing anemia are associated with increased oxidative stress in erythrocytes, including sickle-cell anemia (39, 40) , thalassemia (35, 93) , G6PD-deficiency (84) , and malaria (34) . Consequently, erythrocytes of individuals with sickle-cell anemia, thalassemia, G6PD deficiency, or malaria show decreased GSH levels (9, 73) . Along those lines, individuals with alterations of genes linked to GSH metabolism have been reported to present with enhanced oxidative cell damage or anemia (46) . Moreover, polymorphisms of glutathione S-transferase genotypes seem to be associated not only with certain types of anemia but also with the severity of malarial anemia (48) . Increasing malarial parasitemia causes a more severe drop in the GSH content of erythrocytes (9) . The present observations do suggest that the clinical use of DMF may be limited by enhanced PS exposure in patients with eryptosis-associated disease or treated in parallel with substances triggering eryptosis.
The present observations unravel an additional PS exposurerelated therapeutic effect of DMF, i.e., the substantial influence of DMF treatment on the in vitro amplification of P. falciparum in human erythrocytes and parasitemia, as well as on the survival of P. berghei-infected mice. Similar to earlier observations (42) , the infection of untreated mice with P. berghei took an invariably lethal course within Ͻ20 days. In contrast, 60% of the DMF-treated mice did survive the infection.
Several eryptosis-inducing diseases and substances have already been shown to favorably influence the course of malaria (28), i.e., sickle-cell trait, ␤-thalassemia-trait, G6PD deficiency (4, 64, 67) , iron deficiency (53), lead (54), chlorpromazine (55) , and cyclosporine (13, 57) . Thus, the stimulation of cell membrane scrambling or eryptosis is presumably a key event for the protective effect of DMF during malaria. It should be kept in mind, though, that the protective effect may have partially been due to interference with other mechanisms, such as a direct toxic action on the parasite by depletion of glutathione. Interestingly, the parasite itself contains antioxidative mechanisms. The genes of the two GSH catalyzing enzymes, ␥-glutamylcysteine synthetase (␥-GCS) and glutathione synthetase, as well as thioredoxin have all been isolated from Plasmodium spp. (72, 77) . Furthermore, it has been suggested that GSH predominantly synthesized by parasitic enzymes sustains the antioxidative scavenger pool in infected erythrocytes (3). The parasitic ␥-GCS plays a crucial role for GSH synthesis and parasite survival (92) . Genetic disruption of the ␥-GCS gene in P. berghei resulted in significant decrease of the GSH content of the blood stage parasite. Moreover, in vivo proliferation of parasites lacking the ␥-GCS gene was strongly impaired in mice and parasite development was impaired in mosquitoes (98) . This might be explained by uncontrolled accumulation of ROS, which are involved in the antiparasitic defense of mosquitoes like Anopheles gambiae (79) . Excessive ROS is harmful for both the parasite and its vector and may lead to parasitic death and subsequent death of Anopheles. Similarly, the GSH-depleting compound DMF may favorably influence the course of malaria by preferential induction of cell membrane scrambling in Plasmodium-infected erythrocytes. Additional experiments are needed to clarify the mechanisms underlying the remarkable effect of DMF on parasitemia and mouse survival in vivo.
Because of the high prevalence of malaria and frequent resistance to antimalarial drugs there is urgent need of new safe and effective therapeutics (27) . GSH seems to be an ideal therapeutic target since this tripeptide is crucial for the survival of the parasite and its host cell. A compound like DMF that efficiently depletes intracellular GSH stores could be beneficial as antimalarial therapy in combination with established antimalarial drugs like chloroquine, since Plasmodium resistance to chloroquine and other drugs has been linked to high GSH levels (37) . DMF may overcome this resistance, since DMF directly depletes the GSH stores of erythrocytes. By causing rapid PS exposure of GSH-depleted erythrocytes, Plasmodia kill their host cells and thus limit their own proliferation.
In conclusion, exposure of erythrocytes to DMF triggers cell membrane scrambling and cell shrinkage, typical features of suicidal erythrocyte death. The eryptotic effect of DMF is mediated by directly targeting erythrocyte GSH reservoirs. It may further accelerate the clearance of erythrocytes from circulating blood and thus predispose to the development of anemia. Importantly, DMF therapy does not result in anemia when treating healthy, noninfected mice. In contrast, in the in vivo setting of malaria, DMF seems to induce PS exposure selectively in cells with already altered GSH metabolism, suggesting that oxidatively stressed erythrocytes are the target cells of additional GSH depletion by DMF. In malaria-infected patients, predisposition to PS exposure by the drug DMF should accelerate the death of Plasmodium-infected erythrocytes and thus significantly blunt the development of parasitemia. Accordingly, first in vivo studies with mice revealed that orally applied DMF can indeed prevent the otherwise invariably lethal course of the disease in the majority of infected animals. The oral administration of this small molecule and its uncomplex structure make this compound affordable for antimalarial strategies in humans. Moreover, as DMF targets the host cell and not the pathogen, DMF is not expected to trigger resistance of the pathogen.
